Bristol-Myers Squibb Co (BRM.HA)
Hanover - Hanover Delayed price. Currency in EUR
Add to watchlist
As of 08:01AM CEST. Market open.
| Previous close | 46.24 |
| Open | 45.60 |
| Bid | 45.46 x 0 |
| Ask | 45.92 x 0 |
| Day's range | 45.60 - 45.60 |
| 52-week range | 36.49 - 55.10 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 31 Oct 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireU.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
PRINCETON, N.J., September 27, 2024--U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
Barrons.comThese Stocks Moved the Most Today: Bristol Myers, Costco, EchoStar, Cassava, DJT, Wynn, HP Inc., Acadia Healthcare, and More
Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter revenue at Costco misses analysts’ estimates, and EchoStar rises on reports its Dish subsidiary is in merger talks with DirecTV.
Business WireBristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting
PRINCETON, N.J., September 27, 2024--BMS Presents New Data from Two Trials Demonstrating Sotyktu Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting
© 2024 Yahoo. All rights reserved.